Last Updated: September 23, 2026

Merck Sharp Dohme Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for MERCK SHARP DOHME

MERCK SHARP DOHME has twenty approved drugs.

There are twenty US patents protecting MERCK SHARP DOHME drugs.

Summary for Merck Sharp Dohme

US Patents:	20
Tradenames:	16
Ingredients:	16
NDAs:	20

Drugs and US Patents for Merck Sharp Dohme

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	PREVYMIS	letermovir	TABLET;ORAL	209939-002	Nov 8, 2017		RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-003	Aug 13, 2014		RX	Yes	No	11,980,623	⤷ Start Trial	Y			⤷ Start Trial
Merck Sharp Dohme	WELIREG	belzutifan	TABLET;ORAL	215383-001	Aug 13, 2021		RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
Merck Sharp Dohme	WELIREG	belzutifan	TABLET;ORAL	215383-001	Aug 13, 2021		RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Merck Sharp Dohme

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-006	Sep 18, 2012	7,459,428	⤷ Start Trial
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-006	Sep 18, 2012	7,078,381	⤷ Start Trial
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-006	Sep 18, 2012	6,890,898	⤷ Start Trial
Merck Sharp Dohme	JUVISYNC	simvastatin; sitagliptin phosphate	TABLET;ORAL	202343-006	Sep 18, 2012	6,303,661	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for MERCK SHARP DOHME drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	140 mg and 180 mg	➤ Subscribe	2008-03-24
➤ Subscribe	Delayed-release Tablets	100 mg	➤ Subscribe	2014-06-16
➤ Subscribe	Tablets	100 mg/10 mg and 100 mg/40 mg	➤ Subscribe	2012-06-19
➤ Subscribe	Tablets	50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg	➤ Subscribe	2012-11-06
➤ Subscribe	Oral Suspension	40 mg/mL	➤ Subscribe	2011-02-28
➤ Subscribe	Injection	18 mg/mL, 16.7 mL vials	➤ Subscribe	2015-11-24
➤ Subscribe	Tablets	100 mg/10 mg and 100 mg/40 mg	➤ Subscribe	2012-06-25

International Patents for Merck Sharp Dohme Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Slovenia	3043784	⤷ Start Trial
Lithuania	3417851	⤷ Start Trial
Mexico	2014010323	⤷ Start Trial
South Korea	20130114603	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Merck Sharp Dohme Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1620113	300756	Netherlands	⤷ Start Trial	PRODUCT NAME: IVERMECTINE VOOR TOEPASSING IN DE BEHANDELING VAN ROSACEA; NATIONAL REGISTRATION NO/DATE: RVG 115310 20150504; FIRST REGISTRATION: MT MA117/01101 20150402
1620113	15C0069	France	⤷ Start Trial	PRODUCT NAME: IVERMECTINE; NAT. REGISTRATION NO/DATE: NL 44511 20150721; FIRST REGISTRATION: MT - MA 117/01101 20150402
1385870	C300506	Netherlands	⤷ Start Trial	PRODUCT NAME: BOCEPREVIR, OF EEN ENANTIOMEER, STEREOISIOMEER, ROATMEER, TAUTOMEER OF RACEMAAT VAN DIE VERBINDING, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT; REGISTRATION NO/DATE: EU/1/11/704/001 20110718
1622880	CA 2018 00026	Denmark	⤷ Start Trial	PRODUCT NAME: LETERMOVIR, OR ITS SALT, SOLVATE OR SOLVATE OF ITS SALT; REG. NO/DATE: EU/1/17/1245 20180110
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.